Pharma Focus America

MilliporeSigma to Acquire Mirus Bio, Expanding Role in Viral Vector Manufacturing

Thursday, May 23, 2024

MilliporeSigma, the U.S. and Canada arm of Merck KGaA, Darmstadt, Germany's Life Science business, has recently finalized a significant acquisition deal worth US$ 600 million with Mirus Bio, a Madison, Wisconsin-based life science company under Gamma Biosciences. Specializing in transfection reagents crucial for viral vector-based gene therapies, Mirus Bio brings a wealth of expertise to the table, particularly with products like TransIT-VirusGEN®.

Matthias Heinzel, a Member of the Executive Board and CEO Life Science at Merck KGaA, emphasized the burgeoning potential of viral vector-based cell and gene therapies, citing over 20 approvals in the last decade and a projected 30% growth until 2028. This acquisition, Heinzel adds, combined with Merck's expansive portfolio, aims to meet the escalating demand for these life-saving therapies.

Mirus Bio, expressed enthusiasm about the acquisition, highlighting the synergies between Mirus Bio's leading transfection reagents and MilliporeSigma's global reach and resources. Gordon believes this union will propel their business to greater heights, enabling them to serve more customers and, ultimately, benefit more patients worldwide.

MilliporeSigma's Process Solutions business, renowned for its comprehensive product portfolio, offers flexible solutions for viral vector manufacturing, spanning from preclinical to commercial stages. The acquisition enhances this portfolio, complementing it with Mirus Bio's expertise in nucleic acid delivery. Moreover, MilliporeSigma's Life Science Services arm offers contract testing and comprehensive CDMO services for viral vector manufacturing, further streamlining the path to commercialization for cell and gene therapies.

The deal, expected to close in the third quarter of 2024 pending regulatory approvals and customary closing conditions, underscores Merck KGaA's commitment to advancing healthcare through strategic investments and partnerships.

Merck KGaA, Darmstadt, Germany's Life Science business, operating as MilliporeSigma in the U.S. and Canada, boasts a global workforce of over 28,000 employees and operates more than 55 manufacturing and testing sites worldwide. With a portfolio exceeding 300,000 products focused on scientific discovery, biomanufacturing, and testing services, Merck KGaA, Darmstadt, Germany, continues to make significant contributions to the healthcare, life sciences, and electronics sectors.

The company, with a sales figure of €21 billion in 2023 across 65 countries, is renowned for its commitment to scientific exploration and responsible entrepreneurship since its founding in 1668. 

 

Source: businesswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024